HOLX vs. QGEN, PHG, CUTR, BDX, EW, DXCM, IDXX, RMD, STE, and BAX
Should you be buying Hologic stock or one of its competitors? The main competitors of Hologic include Qiagen (QGEN), Koninklijke Philips (PHG), Cutera (CUTR), Becton, Dickinson and Company (BDX), Edwards Lifesciences (EW), DexCom (DXCM), IDEXX Laboratories (IDXX), ResMed (RMD), STERIS (STE), and Baxter International (BAX).
Hologic (NASDAQ:HOLX) and Qiagen (NYSE:QGEN) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, analyst recommendations, community ranking, institutional ownership, media sentiment, valuation, dividends, earnings and profitability.
Hologic has higher revenue and earnings than Qiagen. Qiagen is trading at a lower price-to-earnings ratio than Hologic, indicating that it is currently the more affordable of the two stocks.
Hologic has a beta of 1.01, suggesting that its share price is 1% more volatile than the S&P 500. Comparatively, Qiagen has a beta of 0.42, suggesting that its share price is 58% less volatile than the S&P 500.
Hologic received 611 more outperform votes than Qiagen when rated by MarketBeat users. Likewise, 69.76% of users gave Hologic an outperform vote while only 60.79% of users gave Qiagen an outperform vote.
Hologic currently has a consensus target price of $85.60, indicating a potential upside of 16.02%. Qiagen has a consensus target price of $50.95, indicating a potential upside of 17.77%. Given Qiagen's stronger consensus rating and higher possible upside, analysts plainly believe Qiagen is more favorable than Hologic.
In the previous week, Hologic had 9 more articles in the media than Qiagen. MarketBeat recorded 13 mentions for Hologic and 4 mentions for Qiagen. Qiagen's average media sentiment score of 0.97 beat Hologic's score of 0.91 indicating that Qiagen is being referred to more favorably in the news media.
94.7% of Hologic shares are owned by institutional investors. Comparatively, 70.0% of Qiagen shares are owned by institutional investors. 1.8% of Hologic shares are owned by company insiders. Comparatively, 9.0% of Qiagen shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
Qiagen has a net margin of 17.38% compared to Hologic's net margin of 11.78%. Hologic's return on equity of 18.91% beat Qiagen's return on equity.
Summary
Hologic beats Qiagen on 12 of the 18 factors compared between the two stocks.
Get Hologic News Delivered to You Automatically
Sign up to receive the latest news and ratings for HOLX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding HOLX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
